On April 4, 2019, we entered into an underwriting agreement (the Underwriting Agreement) with Cowen and Company, LLC, Wells
Fargo Securities, LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the Underwriters), relating to the issuance and sale of 11,000,000 shares of our common stock. The price to the
public in this offering is $11.50 per share, and the Underwriters have agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $10.81 per share. All of the shares being sold in this offering are being sold by
Sangamo. The net proceeds to Sangamo from this offering are expected to be approximately $118.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is expected to
close on or about April 8, 2019, subject to customary closing conditions. In addition, under the terms of the Underwriting Agreement, we have granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,650,000
shares of our common stock. Sangamo anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including support for its own and its partnered gene therapy, genome editing, cell therapy and gene
regulation product candidates and research programs, its manufacturing facilities and other business development activities.
The
Underwriting Agreement contains customary representations, warranties and agreements by us, customary conditions to closing, indemnification obligations of Sangamo and the Underwriters, including for liabilities under the Securities Act of 1933, as
amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the
benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties.
The offering is being made
pursuant to Sangamos effective registration statement on Form
S-3
(Registration Statement
No. 333-224418)
previously filed with the Securities and Exchange
Commission and a prospectus supplement.
The foregoing is only a brief description of the terms of the Underwriting Agreement, does not
purport to be a complete statement of the rights and obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Underwriting Agreement that is filed as
Exhibit 1.1 hereto. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.
Forward-Looking Statements
This report
contains forward-looking statements, including, without limitation, statements relating to Sangamos expectations regarding the closing of the public offering and the anticipated use of net proceeds from the offering. These forward-looking
statements are based upon Sangamos current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties related to the
satisfaction of customary closing conditions related to the public offering or factors that could result in changes to Sangamos anticipated use of proceeds. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this report. Sangamo undertakes no duty to update such information except as required under applicable law.